Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Mammary Carcinoma, Human”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Testing effectiveness (Phase 2)Looking for participantsNCT07222215
What this trial is testing

PhII Randomized CAPecitabine + ELAcestrant vs. Capecitabine Alone in ER+ Breast Cancer (CAPELA)

Who this might be right for
Estrogen-receptor-positive Breast CancerMetastatic Breast CancerBreast Cancer+6 more
Kristina A. Fanucci 297
Early research (Phase 1)Active Not RecruitingNCT05081492
What this trial is testing

CF33-hNIS-antiPDL1 for the Treatment of Metastatic Triple Negative Breast Cancer

Who this might be right for
Anatomic Stage IV Breast Cancer AJCC v8Metastatic Triple-Negative Breast CarcinomaPrognostic Stage IV Breast Cancer AJCC v8
City of Hope Medical Center 9
Not applicableLooking for participantsNCT06106477
What this trial is testing

Impact of Intermittent Fasting on Biomarkers of Inflammation and Health-Related Quality of Life: A Feasibility Trial for Women With HR+/HER2- Early Breast Cancer

Who this might be right for
Breast Cancer
Medical College of Wisconsin 20
Testing effectiveness (Phase 2)Study completedNCT00773695
What this trial is testing

Bevacizumab (Avastin) in Combination With Neoadjuvant Treatment Regimens in Participants With Primary Human Epidermal Growth Factor Receptor 2 (HER2) Negative Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 150
Testing effectiveness (Phase 2)Study completedNCT00217672
What this trial is testing

Docetaxel With Bevacizumab as First-Line Therapy in Treating Women With Stage IV Breast Cancer

Who this might be right for
Breast Cancer
Translational Oncology Research International 76
Large-scale testing (Phase 3)Looking for participantsNCT06058377
What this trial is testing

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Who this might be right for
Anatomic Stage II Breast Cancer AJCC v8Anatomic Stage III Breast Cancer AJCC v8HER2-Negative Breast Carcinoma+1 more
National Cancer Institute (NCI) 3,680
Testing effectiveness (Phase 2)Study completedNCT02069093
What this trial is testing

Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer

Who this might be right for
Advanced Breast Cancer
Novartis Pharmaceuticals 92
Early research (Phase 1)Ended earlyNCT04025216
What this trial is testing

CART-TnMUC1 in Patients With TnMUC1-Positive Advanced Cancers

Who this might be right for
Non-Small Cell Lung CancerOvarian CancerFallopian Tube Cancer+3 more
Kite, A Gilead Company 16
Early research (Phase 1)UnknownNCT02725606
What this trial is testing

Study to Assess the Safety, Tolerability, and Pharmacokinetics/Pharmacodynamics of GW003 in Patients With Breast Cancer

Who this might be right for
Chemotherapy-induced Neutropenia
Jiangsu T-Mab Biopharma Co.,Ltd 30
Testing effectiveness (Phase 2)UnknownNCT00066547
What this trial is testing

Monoclonal Antibody Therapy in Treating Women With Locally Advanced or Metastatic Breast Cancer Previously Treated With Combination Chemotherapy

Who this might be right for
Breast Cancer
Jonsson Comprehensive Cancer Center
Large-scale testing (Phase 3)Study completedNCT01572038
What this trial is testing

Pertuzumab in Combination With Trastuzumab (Herceptin) and a Taxane in First-Line Treatment in Participants With Human Epidermal Growth Factor 2 (HER2)-Positive Advanced Breast Cancer

Who this might be right for
Breast Neoplasms
Hoffmann-La Roche 1,436
Large-scale testing (Phase 3)Study completedNCT03084939
What this trial is testing

Efficacy and Safety of Trastuzumab Emtansine in Chinese Participants With Human Epidermal Growth Factor Receptor 2 (HER2)-Positive Locally Advanced or Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Hoffmann-La Roche 351
Early research (Phase 1)Looking for participantsNCT07545122
What this trial is testing

A Phase 1a/1b, First-Time-in-Human Study of CT-202, a Nectin-4 Directed Bispecific Antibody, in Participants With Recurring Triple Negative Breast, Colorectal, Urothelial Cancers

Who this might be right for
Triple Negative Breast Cancer (TNBC)Colorectal CancerUrothelial Cancer
Context Therapeutics Inc. 162
Testing effectiveness (Phase 2)Looking for participantsNCT06249048
What this trial is testing

Phase 1/2 Study of Intratumoral Injection of STX-001 in Advanced Solid Tumors as Monotherapy or in Combination With Pembrolizumab

Who this might be right for
Advanced Solid Tumor
Strand Therapeutics Inc. 108
Early research (Phase 1)Ended earlyNCT01805908
What this trial is testing

Imaging With 111 Indium (111In)-Pertuzumab (PmAb) to Predict Response to Trastuzumab (TmAb) in Human Epidermal Growth Factor-2 (HER2) Positive Metastatic Breast Cancer (MBC) or Locally Advanced Breast Cancer (LABC)

Who this might be right for
Breast Cancer
Ontario Clinical Oncology Group (OCOG) 3
Testing effectiveness (Phase 2)Active Not RecruitingNCT06702618
What this trial is testing

Evaluation of TQB3616 Capsules in a Phase II Clinical Trial for Recurrent/Metastatic Breast Cancer

Who this might be right for
Breast Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd. 33
Not applicableEnded earlyNCT02611310
What this trial is testing

Observe Treatment Patterns and Outcomes in Participants in Saudi Arabia With Human Epidermal Growth Factor Receptor 2 (HER2-Positive) Unresectable Locally Advanced or Metastatic Breast Cancer (LA/mBC)

Who this might be right for
Metastatic Breast Cancer
Hoffmann-La Roche 15
Testing effectiveness (Phase 2)Study completedNCT01268150
What this trial is testing

Single-Agent Eribulin Mesylate as First-Line Therapy for Locally Recurrent or Metastatic Human Epidermal Growth Factor Receptor Two (HER2) Negative Breast Cancer

Who this might be right for
Locally RecurrentMetastatic Breast Cancer ( HER2 Negative)
Eisai Inc. 56
Large-scale testing (Phase 3)Ended earlyNCT05128773
What this trial is testing

Study of Amcenestrant (SAR439859) Versus Tamoxifen for Patients With Hormone Receptor-positive (HR+) Early Breast Cancer, Who Have Discontinued Adjuvant Aromatase Inhibitor Therapy Due to Treatment-related Toxicity

Who this might be right for
Breast Cancer
Sanofi 3
Testing effectiveness (Phase 2)WithdrawnNCT01410708
What this trial is testing

TORI 104 Pre-Surgical Dasatinib

Who this might be right for
Breast Cancer
AHS Cancer Control Alberta
Next Page